172 related articles for article (PubMed ID: 22257213)
1. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Singh R; Masuda ES; Payan DG
J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
[No Abstract] [Full Text] [Related]
2. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
3. Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Zhao H; Caflisch A
Bioorg Med Chem Lett; 2014 Mar; 24(6):1523-7. PubMed ID: 24569110
[TBL] [Abstract][Full Text] [Related]
4. Syk kinase as a treatment target for therapy in autoimmune diseases.
Kyttaris VC; Tsokos GC
Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
6. Activation of spleen tyrosine kinase (Syk) at fertilization in Rhinella arenarum eggs.
Mouguelar VS; Coux G
Int J Dev Biol; 2014; 58(10-12):811-8. PubMed ID: 26154322
[TBL] [Abstract][Full Text] [Related]
7. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
8. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
9. Syk kinase inhibitors in allergic diseases.
Denyer J; Patel V
Drug News Perspect; 2009 Apr; 22(3):146-50. PubMed ID: 19440557
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
Norman P
Expert Opin Ther Pat; 2012 Mar; 22(3):335-9. PubMed ID: 22356552
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70.
Vu CB; Corpuz EG; Merry TJ; Pradeepan SG; Bartlett C; Bohacek RS; Botfield MC; Eyermann CJ; Lynch BA; MacNeil IA; Ram MK; van Schravendijk MR; Violette S; Sawyer TK
J Med Chem; 1999 Oct; 42(20):4088-98. PubMed ID: 10514279
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal B-cell antigen receptor signaling activity in vivo elicits germinal center counterselection mechanisms.
Königsberger S; Weis V; Prodöhl J; Stehling M; Hobeika E; Reth M; Kiefer F
Eur J Immunol; 2015 Feb; 45(2):603-11. PubMed ID: 25382621
[TBL] [Abstract][Full Text] [Related]
13. Structural and biophysical characterization of the Syk activation switch.
Grädler U; Schwarz D; Dresing V; Musil D; Bomke J; Frech M; Greiner H; Jäkel S; Rysiok T; Müller-Pompalla D; Wegener A
J Mol Biol; 2013 Jan; 425(2):309-33. PubMed ID: 23154170
[TBL] [Abstract][Full Text] [Related]
14. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
15. Discovery and profiling of a selective and efficacious Syk inhibitor.
Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
[TBL] [Abstract][Full Text] [Related]
16. Interdomain A is crucial for ITAM-dependent and -independent regulation of Syk.
Adachi T; Wienands J; Tsubata T; Kurosaki T
Biochem Biophys Res Commun; 2007 Dec; 364(1):111-7. PubMed ID: 17936247
[TBL] [Abstract][Full Text] [Related]
17. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
[TBL] [Abstract][Full Text] [Related]
18. Sesquiterpene dimmer (DSF-27) inhibits the release of neuroinflammatory mediators from microglia by targeting spleen tyrosine kinase (Syk) and Janus kinase 2 (Jak2): Two major non-receptor tyrosine signaling proteins involved in inflammatory events.
Zeng KW; Wang S; Dong X; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2014 Mar; 275(3):244-56. PubMed ID: 24486434
[TBL] [Abstract][Full Text] [Related]
19. Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Li M; Luraghi P; Amour A; Qian XD; Carter PS; Clark CJ; Deakin A; Denyer J; Hobbs CI; Surby M; Patel VK; Schaefer EM
Anal Biochem; 2009 Jan; 384(1):56-67. PubMed ID: 18762159
[TBL] [Abstract][Full Text] [Related]
20. Anchor-based classification and type-C inhibitors for tyrosine kinases.
Hsu KC; Sung TY; Lin CT; Chiu YY; Hsu JT; Hung HC; Sun CM; Barve I; Chen WL; Huang WC; Huang CT; Chen CH; Yang JM
Sci Rep; 2015 Jun; 5():10938. PubMed ID: 26077136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]